CME Presentations

GnRH


Presentations


Speakers

  • Neal D. Shore, MD, FACS

    Neal D. Shore, MD, FACS

    Neal D. Shore, MD, FACS

    Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina.

    Dr. Shore has conducted more than 350 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Bladder Cancer Advocacy Network, and is Immediate Past President, Large Urology Group Practice Association. He is a founder for both: CUSP Clinical Trials Consortium, as well as for DASHKO, large urology practices data registries. He serves as the National Urology Research Director for 21st Century Oncology. He has served on the AUA Male Health Committee and the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank and the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE(Academic Editor), Urology Practice, World Journal of Urology, and serves as Editor, Everyday Urology-Oncology. He has more than 175 peer reviewed publications and numerous book chapters; he performs peer review for Lancet Oncology, New England Journal of Medicine, European Urology, Journal Urology, Urology, BJUI, PCPD, and numerous other high impact scientific journals.

    A graduate of Duke University and Duke University Medical School, Dr. Shore completed a 6-month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.
  • Alicia Morgans, MD, MPH

    Alicia Morgans, MD, MPH

    Alicia Morgans, MD, MPH

    Genitourinary Medical Oncologist

    Alicia Morgans, MD, MPH, is a Genitourinary Medical Oncologist and the Medical Director of the Survivorship Program at Dana-Farber Cancer Institute. Her research has investigated complications of systemic therapy for prostate cancer survivors, including the study of skeletal, cardiovascular, diabetic, and cognitive complications. Dr. Morgans is a member of the advanced and localized prostate cancer treatment guidelines committees of the American Urologic Association and a member of the cardio-oncology committee of American Heart Association. Since 2016, she has been the President of the Medical Advisory Board for ZERO, a non-profit organization dedicated to supporting education and research funding for prostate cancer research.

CME Information

Global Logo PQH Logo

Practical Strategies for Multidisciplinary Management and Patient Adherence

This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the Large Urology Group Practice Association (LUGPA).

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Pfizer Inc and Myovant Sciences Ltd.

DATE OF RELEASE/EXPIRATION

This activity will be released on November 9 and is valid until May 9, 2022. Requests for credit must be made no later than May 9, 2022.

TARGET AUDIENCE

The educational design of this activity addresses the needs of urologists, medical oncologists, radio-oncologists, radiologists, cardiologists, and cardio-oncologists, and other allied health members managing patients on ADTs.

STATEMENT OF NEED/PROGRAM OVERVIEW

Multidisciplinary care strategies extend to managing the cardiological effects of androgen deprivation therapy (ADT). Urology, oncology, and cardiovascular specialists is necessary to optimally manage patients on ADTs, minimize vascular and metabolic toxicity, and mitigate long-term adverse effects. Joint scientific recommendations and expert consensus groups have called for the assessment and subsequent mitigation of cardiovascular risk factors.

Join a panel of expert clinicians for 2 on-demand sessions exploring multidisciplinary strategies, in the management of prostate cancer. This session will detail the importance of a multidisciplinary approach to the care of prostate cancer. Benefits such as effective management of adverse reactions, improved patient counseling, and optimal patient adherence to treatment will be discussed.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:
  • Identify the need for multidisciplinary strategies, including cardiology/cardio-oncology, in the care of patients using ADT
  • Assess team‐based strategies to improve adverse‐event management and oral adherence
  • Discuss patient and caregiver counseling to improve treatment decision‐making and outcomes

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 30 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter Reported Financial Relationship
Neal D. Shore, MD, FACS
Medical Director, CPI
Carolina Urologic Research Center
Atlantic Urology Clinics

Consulting Fee: Abbvie, Amgen, Astellas, Astra Zeneca, Bayer, BMS, Boston Scientific, Clovis Oncology, Cold Genesys, Dendreon, Exact Imaging, Exact Sciences, FerGene, Foundation Medicine, Genesis Care, Invitae, Janssen, MDxhealth, Merck, Myovant, Myriad, Nymox, Pacific Edge, Pfizer, Phosphorous, Propella, PreView, Sanofi Genzyme, Speciality Networks, Sesen Bio, Tolmar, Urogen Speakers’ Bureau: Astellas, AstraZeneca, Bayer, Clovis Oncology, Foundation Medicine, Janssen, Merck, Pfizer, Guardant Health
Alicia Morgans, MD, MPH
Genitourinary Medical Oncologist
Medical Director, Survivorship Program
Dana-Farber Cancer Institute
Consulting Fee: Astellas, AstraZeneca, AAA, Bayer, Clovis, Exelixis, Dendreon, Janssen, Lantheus, Merck, Myovant, Myriad, Novartis, Pfizer, Sanofi, Seattle Genetics
Contracted Research: Bayer, Myovant, Seattle Genetics, Astellas
Honoraria: Astellas, AstraZeneca, Janssen, Merck, Myovant, Pfizer, Sanofi

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager Reported Financial Relationship
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Kim Rodriguez Nothing to disclose
Tariqa Ackbarali Nothing to disclose
Alissa Yost Nothing to disclose

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact UroCareLive at 877-394-1306 or at Info@UroCareLive.com.
Global Logo PQH Logo

LHRH Agonists vs GnRH Antagonists: Setting Treatment Goals with Patients

This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the Large Urology Group Practice Association (LUGPA).

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Pfizer Inc and Myovant Sciences Ltd.

DATE OF RELEASE/EXPIRATION

This activity will be released on November 9 and is valid until May 9, 2022. Requests for credit must be made no later than May 9, 2022.

TARGET AUDIENCE

The educational design of this activity addresses the needs of urologists, medical oncologists, radio-oncologists, radiologists, cardiologists, and cardio-oncologists, and other allied health members managing patients on ADTs.

STATEMENT OF NEED/PROGRAM OVERVIEW

While androgen deprivation therapy (ADT) is an effective treatment for patients with advanced prostate cancer, optimal patient outcomes are dependent upon several factors. Clinicians should know how to differentiate between luteinizing hormone-releasing hormone (LHRH) agonists and gonadotropin-releasing hormone (GnRH) antagonists, and should recognize newly approved oral ADTs, their potential benefits, risks for adverse events, and related barriers to adherence.

Join a panel of expert clinicians for 2 on-demand sessions exploring the use of anti-ADT in the management of prostate cancer. This session will review the rationale behind ADT options to improve patient outcomes. Differences between LHRH and GnRH options, including mechanisms of action, modes of administration, and safety profiles, will be reviewed with an eye toward setting effective treatment goals with patients.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:
  • Summarize the pharmacologic differences between current LHRH agonists and GnRH antagonists
  • Describe the latest safety and efficacy data, as well as the cardiovascular risk profiles, of ADT

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 30 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter Reported Financial Relationship
Neal D. Shore, MD, FACS
Medical Director, CPI
Carolina Urologic Research Center
Atlantic Urology Clinics

Consulting Fee: Abbvie, Amgen, Astellas, Astra Zeneca, Bayer, BMS, Boston Scientific, Clovis Oncology, Cold Genesys, Dendreon, Exact Imaging, Exact Sciences, FerGene, Foundation Medicine, Genesis Care, Invitae, Janssen, MDxhealth, Merck, Myovant, Myriad, Nymox, Pacific Edge, Pfizer, Phosphorous, Propella, PreView, Sanofi Genzyme, Speciality Networks, Sesen Bio, Tolmar, Urogen Speakers’ Bureau: Astellas, AstraZeneca, Bayer, Clovis Oncology, Foundation Medicine, Janssen, Merck, Pfizer, Guardant Health
Alicia Morgans, MD, MPH
Genitourinary Medical Oncologist
Medical Director, Survivorship Program
Dana-Farber Cancer Institute
Consulting Fee: Astellas, AstraZeneca, AAA, Bayer, Clovis, Exelixis, Dendreon, Janssen, Lantheus, Merck, Myovant, Myriad, Novartis, Pfizer, Sanofi, Seattle Genetics
Contracted Research: Bayer, Myovant, Seattle Genetics, Astellas
Honoraria: Astellas, AstraZeneca, Janssen, Merck, Myovant, Pfizer, Sanofi

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager Reported Financial Relationship
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Kim Rodriguez Nothing to disclose
Tariqa Ackbarali Nothing to disclose
Alissa Yost Nothing to disclose

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact UroCareLive at 877-394-1306 or at Info@UroCareLive.com.